Table 2. CD73 expression in tumor cells by H-score category and association with clinicopathological features.
| Variable | H-score 0 N (%) |
H-score 2.5–37.5 N (%) |
H-score > 37.5–285 N (%) |
2.5–37.5 vs. 0 RRR (P-value) |
>37.5–285 vs. 0 RRR (P-value) |
Global P-value |
|---|---|---|---|---|---|---|
| Age1 mean (±sd) | 62.8 (±15.3) | 63.2 (±14.9) | 68.2 (±12.5) | 1.00 (0.903) | 1.02 (0.118) | 0.241 |
| Gender | 0.482 | |||||
| Male (ref.) | 22 (42.3%) | 18 (51.4%) | 15 (55.6%) | − | − | |
| Female | 30 (57.7%) | 17 (48.6%) | 12 (44.4%) | 0.69 (0.403) | 0.59 (0.265) | |
| Melanoma type2 | 0.578 | |||||
| Cutaneous (ref.) | 39 (75.0%) | 29 (82.9%) | 22 (81.5%) | − | − | |
| Mucosal | 1 (1.9%) | 0 | 0 | 4.59e–07 (0.993) | 4.67e–07 (0.994) | |
| Ocular | 6 (11.5%) | 4 (11.4%) | 1 (3.7%) | 0.90 (0.874) | 0.30 (0.273) | |
| Unknown primary site | 6 (11.5%) | 2 (5.7%) | 4 (14.8%) | 0.45 (0.347) | 1.18 (0.811) | |
| Initial T stage | 0.086 | |||||
| T1-2 (ref.) | 9 (21.4%) | 13 (41.9%) | 10 (43.5%) | − | − | |
| T3-4 | 33 (78.6%) | 18 (58.1%) | 13 (56.5%) | 0.38 (0.063) | 0.35 (0.066) | |
| Breslow's depth | 5.7 (±8.4) | 2.6 (±1.7) | 3.4 (±3.0) | 0.77 (0.023) | 0.89 (0.201) | 0.011 |
| mean (±sd) | ||||||
| Initial N stage | 0.762 | |||||
| N0 (ref.) | 20 (45.5%) | 10 (40.0%) | 8 (36.4%) | − | − | |
| N1-3 | 24 (54.6%) | 15 (60.0%) | 14 (63.6%) | 1.25 (0.661) | 1.46 (0.482) | |
| Initial M stage | 0.851 | |||||
| M0 (ref.) | 40 (85.1%) | 22 (84.6%) | 20 (80.0%) | − | − | |
| M1 | 7 (14.9%) | 4 (15.4%) | 5 (20.0%) | 1.04 (0.955) | 1.43 (0.581) | |
| BRAF mutation | 0.741 | |||||
| No (ref.) | 18 (48.7%) | 11 (50.0%) | 7 (38.9%) | − | − | |
| Yes | 19 (51.4%) | 11 (50.0%) | 11 (61.1%) | 0.95 (0.920) | 1.49 (0.496) | |
| NRAS mutation | 0.755 | |||||
| No (ref.) | 11 (68.8%) | 6 (54.6%) | 5 (62.5%) | − | − | |
| Yes | 5 (31.3%) | 5 (45.5%) | 3 (37.5%) | 1.83 (0.455) | 1.32 (0.760) | |
| cKIT mutation | 0.567 | |||||
| No (ref.) | 10 (90.9%) | 4 (100.0%) | 4 (100.0%) | − | − | |
| Yes | 1 (9.1%) | 0 | 0 | 2.67e−07 (0.996) | 2.67e−07 (0.996) | |
| Clinical stage1 | 0.275 | |||||
| III (ref.) | 22 (42.3%) | 9 (25.7%) | 10 (37.0%) | − | − | |
| IV | 30 (57.7%) | 26 (74.3%) | 17 (63.0%) | 2.12 (0.116) | 1.25 (0.651) | |
| Biopsy sites | 0.975 | |||||
| LN/skin/Sbc (ref.) | 32 (61.5%) | 21 (60.0%) | 17 (63.0%) | − | − | |
| Lung | 9 (17.3%) | 6 (17.1%) | 3 (11.1%) | 1.02 (0.979) | 0.63 (0.524) | |
| Central nervous system | 3 (5.8%) | 3 (8.6%) | 3 (11.1%) | 0.95 (0.939) | 0.94 (0.929) | |
| Other | 8 (15.4%) | 5 (14.3%) | 4 (14.8%) | 1.52 (0.626) | 1.88 (0.467) | |
| Previous treatments | 0.003 | |||||
| None (ref.) | 42 (80.8%) | 17 (50.0%) | 14 (51.9%) | − | − | |
| CT, RT, TT and/or IT | 10 (19.2%) | 17 (50.0%) | 13 (48.2%) | 4.2 (0.003) | 3.9 (0.009) | |
| TIMC quantity | 0.434 | |||||
| 0 (ref.) | 5 (9.6%) | 1 (2.9%) | 2 (7.4%) | − | − | |
| 1, 2 or 3 | 47 (90.4%) | 34 (97.1%) | 25 (92.6%) | 3.62 (0.250) | 1.33 (0.744) | |
| % of TIMC stained3 | 0.872 | |||||
| 0% (ref.) | 31 (66.0%) | 21 (61.76%) | 17 (68.0%) | − | − | |
| 1–50%4 | 16 (34.0%) | 13 (38.2%) | 8 (32.0%) | 1.20 (0.698) | 0.91 (0.861) |
Abbreviations: CT: chemotherapy; IT: immunotherapy; LN: lymph node; RRR: relative risk ratio (compared to ref.); RT: radiotherapy; Sbc: subcutaneous tissue; TIMC: tumor infiltrating mononuclear cells; TT: targeted therapy.
ref.: variable used as the reference for the statistical analysis.
The P-value was calculated by a univariable multinomial regression analysis. P-values < 0.05 are in bold.
1. At the time of sample collection. 2. Of the primary melanoma. 3. Of the samples containing TIMC (n = 106). 4. As no sample presented more than 50% of TIMC staining, categories above 50% are not represented.